A carregar...
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Two new drugs provide startling benefits in the treatment of age‐related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the c...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1954941/ https://ncbi.nlm.nih.gov/pubmed/17431015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjo.2007.116616 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|